Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity

por Liang, Chris, Yuan, Xiaobin, Shen, Zhilin, Wang, Yang, Ding, Lieming
Publicado 2022

Safety and tolerability of oral vorolanib for neovascular (wet) age-related macular degeneration: a phase I, open-label study

por Gao, Yunxia, Lu, Fang, Li, Xiaoxin, Dai, Hong, Liu, Kun, Liu, Xiaoling, Sun, Zuhua, Xiang, Jin, Ding, Lieming, Liang, Chris, Wang, Yang, Shen, Zhilin, Zhang, Ming
Publicado 2023

TNF-α augments CXCL10/CXCR3 axis activity to induce Epithelial-Mesenchymal Transition in colon cancer cell

por Wang, Zhengcheng, Ao, Xiang, Shen, Zhilin, Ao, Luoquan, Wu, Xiaofeng, Pu, Chengxiu, Guo, Wei, Xing, Wei, He, Min, Yuan, Hongfeng, Yu, Jianhua, Li, Ling, Xu, Xiang
Publicado 2021